Professor John Gibson

Clinical Professor
Medicine, Central Clinical School
Bosch Institute

Telephone +61 2 9515 8031
Fax +61 2 9515 8474

Map

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), Clinical Malignant Haematology, (pp. 847-857). United States: McGraw Hill.
  • Gibson, J., Joshua, D., Ho, J., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), Oxford Handbook of Music Psychology. Oxford, UK: Oxford University Press.
  • Joshua, D., Gibson, J., Brown, R., Ho, J. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), Multiple myeloma and related disorders, (pp. 29-46). UK: Hodder Arnold.

Journals

  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 55(5), 1090-1098. [More Information]
  • Wright, C., Velickovic, Z., Brown, R., Larsen, S., Macpherson, J., Gibson, J., Rasko, J. (2014). Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products. Pathology, 46(3), 177-183. [More Information]
  • Hamadani, M., Saber, W., Ahn, K., Carreras, J., Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale, G., Hari, P., et al (2013). Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biology of Blood and Marrow Transplantation, 19(4), 625-631. [More Information]
  • Maziarz, R., Wang, Z., Zhang, M., Bolwell, B., Chen, A., Fenske, T., Freytes, C., Gale, R., Gibson, J., Hayes-Lattin, B., et al (2013). Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. British Journal of Haematology, 162(5), 648-656. [More Information]
  • Hamadani, M., Saber, W., Ahn, K., Carreras, J., Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale, G., Hari, P., et al (2013). Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biology of Blood and Marrow Transplantation, 19(5), 746-753. [More Information]
  • Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013). Leukaemias into the 21st century - part 2: the chronic leukaemias. Internal Medicine Journal, 43(5), 484-494. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology, 45(1), 81-83. [More Information]
  • Michaelis, L., Saad, A., Zhong, X., Le-Rademacher, J., Freytes, C., Marks, D., Lazarus, H., Bird, J., Holmberg, L., Kamble, R., et al (2013). Salvage second hematopoietic cell transplantation in myeloma. Biology of Blood and Marrow Transplantation, 19(5), 760-766. [More Information]
  • Ahmed, R., King, J., Gibson, J., Halmagyi, M., Gupta, R., Gonzales, M., Buckland, M. (2013). Spinal Leptomeningeal Lymphoma presenting as Pseudotumor Syndrome. Journal of Neuro-Ophthalmology, 33(1), 13-16. [More Information]
  • Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. Blood, 120(10), 2055-2063. [More Information]
  • Chohan, G., Barnett, Y., Gibson, J., Reddel, S., Barnett, M. (2012). Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. Journal of Neurology, Neurosurgery, and Psychiatry, 83(5), 573-575. [More Information]
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal, 42(11), 1179-1186. [More Information]
  • Gibson, J., Weatherburn, C. (2012). Polycythaemia. Medical Observer, 21st August 2012.
  • Ho, J., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia and Lymphoma, 53(9), 1728-1734. [More Information]
  • Brown, R., Suen, H., Favaloro, J., Yang, S., Ho, P., Gibson, J., Joshua, D. (2012). Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. OncoImmunology, 1(9), 1658-1660. [More Information]
  • Nivison-Smith, I., Dodds, A., Doocey, R., Ganly, P., Gibson, J., Ma, D., Simpson, J., Szer, J., Bradstock, K., Bradstock, K. (2011). Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. Leukemia and Lymphoma, 52(9), 1727-1735. [More Information]
  • Passweg, J., Zhang, M., Rocha, V., Kan, F., Champlin, R., Isola, L., Gee, A., Gibson, J., Laughlin, M., Lazarus, H., et al (2011). Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 17(12), 1869-1873. [More Information]
  • Vogl, D., Wang, T., Perez, W., Stadtmauer, E., Heitjan, D., Lazarus, H., Kyle, R., Kamble, R., Weisdorf, D., Roy, V., Gibson, J., et al (2011). Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 17(12), 1765-1774. [More Information]
  • Khoo, T., Vangsted, A., Joshua, D., Gibson, J. (2011). Interferon-Alpha in the Treatment of Multiple Myeloma. Current Drug Targets (online), 12(3), 437-446. [More Information]
  • Brown, R., Langshaw, M., Uhr, E., Gibson, J., Joshua, D. (2011). The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. Medical Journal of Australia, 194(2), 65-67. [More Information]
  • Suryani, S., Fulcher, D., Nanan, B., Nanan, R., Wong, M., Shaw, P., Gibson, J., Williams, A., Tangye, S. (2010). Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood, 115(3), 519-529. [More Information]
  • Reece, D., Vesole, D., Shrestha, S., Zhang, M., Perez, W., Dispenzieri, A., Milone, G., Abidi, M., Atkins, H., Bashey, A., Gibson, J., et al (2010). Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clinical Lymphoma, Myeloma and Leukemia, 10(6), 458-463. [More Information]
  • Hari, P., Majhail, N., Zhang, M., Hassebroek, A., Siddiqui, F., Ballen, K., Bashey, A., Bird, J., Freytes, C., Gibson, J., et al (2010). Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 16(3), 395-402. [More Information]
  • Brown, R., Spencer, A., Ho, J., Kennedy, N., Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson, J., Joshua, D. (2009). Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma, 50(11), 1860-1864. [More Information]
  • Devetten, M., Hari, P., Carreras, J., Logan, B., van Besien, K., Bredeson, C., Freytes, C., Gale, R., Gibson, J., Giralt, S., et al (2009). Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 15(1), 109-117. [More Information]
  • Kumar, S., Perez, W., Zhang, M., Ballen, K., Bashey, A., To, L., Bredeson, C., Cairo, M., Elfenbein, G., Freytes, C., et al (2008). Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 14(10), 1134-1140. [More Information]
  • Bashey, A., Perez, W., Zhang, M., Anderson, K., Ballen, K., Berenson, J., To, L., Fonseca, R., Freytes, C., Gale, R., et al (2008). Comparison of twin and autologous transplants for multiple myeloma. Biology of Blood and Marrow Transplantation, 14(10), 1118-1124. [More Information]
  • Joshua, D., Brown, R., Gibson, J. (2008). Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma, 8(5), 283-286. [More Information]
  • Burgess, P., Robin, H., Langshaw, M., Kershaw, G., Pathiraja, R., Yuen, S., Coad, C., Xiros, N., Mansy, G., Coleman, R., Gibson, J., Joshua, D., et al (2008). Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert Module. International Journal of Laboratory Hematology, Early View 2008(31 (6)), 1-12. [More Information]
  • Grigg, A., Gibson, J., Bardy, P., Reynolds, J., Shuttleworth, P., Koelmeyer, R., Szer, J., Roberts, A., To, L., Kennedy, G., Bradstock, K. (2007). A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biology of Blood and Marrow Transplantation, 13(5), 560-567. [More Information]
  • Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. Molecular Cancer Therapeutics, 6(12), 3365s-3366s.
  • Sanders, J., Crawford, B., Gibson, J., Ho, J., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
  • Feyler, S., Prince, H., Pearce, R., Towlson, K., Nivison-Smith, I., Schey, S., Gibson, J., Patton, N., Bradstock, K., Marks, D., et al (2007). The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplantation, 40(5), 443-450. [More Information]
  • Gibson, J., Anagnostopoulos, A., Hari, P., Pérez, W., Ballen, K., Bashey, A., Bredeson, C., Freytes, C., Gale, R., Gertz, M., et al (2006). Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biology of Blood and Marrow Transplantation, 12(8), 845-854. [More Information]
  • Sze, D., Brown, R., Yang, S., Ho, J., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. Current Cancer Drug Targets, 6(4), 325-331. [More Information]
  • Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, J. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]
  • Gibson, J., Prosser, I., Spencer, A., Horvath, N., Prince, R., Herrmann, R., Bashford, J., Joske, D., Grigg, A., McKendrick, J., et al (2005). Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation, 35(10), 971-7. [More Information]
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. Leukemia and lymphoma, 45(2), 363-371.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β�? In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748.
  • Gibson, J., Ho, J., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic. Transplantation Proceedings, 36(8), 2501-2503. [More Information]
  • Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., Wolf, M., Gibson, J., Schwarer, A., Spencer, A., et al (2004). Interferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia. Annals of Oncology, 15(12), 1810-1815.
  • Horvath, N., Hahn, U., Joshua, D., Dyson, P., Gibson, J., Stevens, J., Rawling, T., Barrow, L., Brown, R., Stephens, S., et al (2004). Long-Term Follow Up Of Sequential Mobilisation And Autologous Transplantation With Cd34-Selected Cells In Multiple Myeloma: A Multimodality Approach. Internal Medicine Journal, 34, 167-175.
  • Gibson, J., Ho, J., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. Transplantation Proceedings, 36(7), 1995-1998. [More Information]
  • Szer, J., Durrant, S., Schwarer, A., Bradstock, K., Gibson, J., Arthur, C., To, L., Hughes, T., Raunow, H. (2004). Oral Versus Intravenous Ganciclovir For The Prophylaxis Of Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation. Internal Medicine Journal, 34(3), 98-101.
  • Ho, J., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. American Journal of Cancer, 3(1), 47-66.
  • Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, J., Raitakari, M., Basten, A., Joshua, D., Fazekas, B. (2003). Clonal Cytotoxic T Cells in Myeloma. Leukemia and lymphoma, 44(10), 1667-1674.
  • Barrow, L., Brown, R., Murray, A., Sze, D., POPE, B., Gibson, J., Hart, D., Joshua, D. (2003). CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination. Leukemia and lymphoma, 44(12), 2117-2122.
  • Gibson, J., et, A. (2003). Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102(10), 3521-3529.
  • Sze, D., Brown, R., Yang, S., Gibson, J., Ho, J., Fazekas, B., Basten, A., Joshua, D. (2003). Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia and lymphoma, 44(9), 1557-1568.
  • Raitakari, M., Brown, R., Gibson, J., Joshua, D. (2003). T cells in myeloma. Hematological Oncology, 21(1), 33-42. [More Information]
  • Ho, J., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. Reviews in Clinical and Experimental Hematology, 6(3), 276-300.
  • Nivison-Smith, I., Bradstock, K., Szer, J., Durrant, S., Dodds, A., Hermann, R., Schwarer, A., Gibson, J., To, L., Arthur, C. (2001). Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplantation, 28(1), 21-27.
  • Sze, D., Giesajtis,, G., Brown, R., Raitakari, M., Gibson, J., Ho, J., Baxter, A., Fazekas, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment. Blood, 98(9), 2817-2827.
  • Brown, R., POPE, B., Murray, A., Esdale, W., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-B1 and interleukin-10. Blood, 98(10), 2992-2998.
  • Ho, J., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood, 97, 490-495.

Conferences

  • Talbot, J., Martin, P., Johnson, L., Beatty, J., Sutton, D., Halliday, C., Gibson, J., Kiddell, L., Steiner, J., Ujvari, B., Barrs, V. (2013). A molecular approach to identification of species causing sinonasal aspergillosis. The Australian Society for Microbiology, Annual Scientific Meeting.
  • Joshua, D., Brown, R., Sze, D., Hodges, P., Gibson, J. (2007). The role of T-cells in myeloma. XIth International Myeloma Workshop & IVth International Workshop on Waldenstrom’s Macroglobulinemia, Italy: Fondazione Ferrata Storti.

2014

  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 55(5), 1090-1098. [More Information]
  • Wright, C., Velickovic, Z., Brown, R., Larsen, S., Macpherson, J., Gibson, J., Rasko, J. (2014). Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products. Pathology, 46(3), 177-183. [More Information]

2013

  • Talbot, J., Martin, P., Johnson, L., Beatty, J., Sutton, D., Halliday, C., Gibson, J., Kiddell, L., Steiner, J., Ujvari, B., Barrs, V. (2013). A molecular approach to identification of species causing sinonasal aspergillosis. The Australian Society for Microbiology, Annual Scientific Meeting.
  • Hamadani, M., Saber, W., Ahn, K., Carreras, J., Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale, G., Hari, P., et al (2013). Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biology of Blood and Marrow Transplantation, 19(4), 625-631. [More Information]
  • Maziarz, R., Wang, Z., Zhang, M., Bolwell, B., Chen, A., Fenske, T., Freytes, C., Gale, R., Gibson, J., Hayes-Lattin, B., et al (2013). Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. British Journal of Haematology, 162(5), 648-656. [More Information]
  • Hamadani, M., Saber, W., Ahn, K., Carreras, J., Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale, G., Hari, P., et al (2013). Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biology of Blood and Marrow Transplantation, 19(5), 746-753. [More Information]
  • Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013). Leukaemias into the 21st century - part 2: the chronic leukaemias. Internal Medicine Journal, 43(5), 484-494. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology, 45(1), 81-83. [More Information]
  • Michaelis, L., Saad, A., Zhong, X., Le-Rademacher, J., Freytes, C., Marks, D., Lazarus, H., Bird, J., Holmberg, L., Kamble, R., et al (2013). Salvage second hematopoietic cell transplantation in myeloma. Biology of Blood and Marrow Transplantation, 19(5), 760-766. [More Information]
  • Ahmed, R., King, J., Gibson, J., Halmagyi, M., Gupta, R., Gonzales, M., Buckland, M. (2013). Spinal Leptomeningeal Lymphoma presenting as Pseudotumor Syndrome. Journal of Neuro-Ophthalmology, 33(1), 13-16. [More Information]

2012

  • Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. Blood, 120(10), 2055-2063. [More Information]
  • Chohan, G., Barnett, Y., Gibson, J., Reddel, S., Barnett, M. (2012). Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. Journal of Neurology, Neurosurgery, and Psychiatry, 83(5), 573-575. [More Information]
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal, 42(11), 1179-1186. [More Information]
  • Gibson, J., Weatherburn, C. (2012). Polycythaemia. Medical Observer, 21st August 2012.
  • Ho, J., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia and Lymphoma, 53(9), 1728-1734. [More Information]
  • Brown, R., Suen, H., Favaloro, J., Yang, S., Ho, P., Gibson, J., Joshua, D. (2012). Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. OncoImmunology, 1(9), 1658-1660. [More Information]

2011

  • Nivison-Smith, I., Dodds, A., Doocey, R., Ganly, P., Gibson, J., Ma, D., Simpson, J., Szer, J., Bradstock, K., Bradstock, K. (2011). Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. Leukemia and Lymphoma, 52(9), 1727-1735. [More Information]
  • Passweg, J., Zhang, M., Rocha, V., Kan, F., Champlin, R., Isola, L., Gee, A., Gibson, J., Laughlin, M., Lazarus, H., et al (2011). Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 17(12), 1869-1873. [More Information]
  • Vogl, D., Wang, T., Perez, W., Stadtmauer, E., Heitjan, D., Lazarus, H., Kyle, R., Kamble, R., Weisdorf, D., Roy, V., Gibson, J., et al (2011). Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 17(12), 1765-1774. [More Information]
  • Khoo, T., Vangsted, A., Joshua, D., Gibson, J. (2011). Interferon-Alpha in the Treatment of Multiple Myeloma. Current Drug Targets (online), 12(3), 437-446. [More Information]
  • Brown, R., Langshaw, M., Uhr, E., Gibson, J., Joshua, D. (2011). The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. Medical Journal of Australia, 194(2), 65-67. [More Information]

2010

  • Suryani, S., Fulcher, D., Nanan, B., Nanan, R., Wong, M., Shaw, P., Gibson, J., Williams, A., Tangye, S. (2010). Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood, 115(3), 519-529. [More Information]
  • Reece, D., Vesole, D., Shrestha, S., Zhang, M., Perez, W., Dispenzieri, A., Milone, G., Abidi, M., Atkins, H., Bashey, A., Gibson, J., et al (2010). Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clinical Lymphoma, Myeloma and Leukemia, 10(6), 458-463. [More Information]
  • Hari, P., Majhail, N., Zhang, M., Hassebroek, A., Siddiqui, F., Ballen, K., Bashey, A., Bird, J., Freytes, C., Gibson, J., et al (2010). Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 16(3), 395-402. [More Information]

2009

  • Brown, R., Spencer, A., Ho, J., Kennedy, N., Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson, J., Joshua, D. (2009). Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma, 50(11), 1860-1864. [More Information]
  • Devetten, M., Hari, P., Carreras, J., Logan, B., van Besien, K., Bredeson, C., Freytes, C., Gale, R., Gibson, J., Giralt, S., et al (2009). Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 15(1), 109-117. [More Information]

2008

  • Kumar, S., Perez, W., Zhang, M., Ballen, K., Bashey, A., To, L., Bredeson, C., Cairo, M., Elfenbein, G., Freytes, C., et al (2008). Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 14(10), 1134-1140. [More Information]
  • Bashey, A., Perez, W., Zhang, M., Anderson, K., Ballen, K., Berenson, J., To, L., Fonseca, R., Freytes, C., Gale, R., et al (2008). Comparison of twin and autologous transplants for multiple myeloma. Biology of Blood and Marrow Transplantation, 14(10), 1118-1124. [More Information]
  • Joshua, D., Brown, R., Gibson, J. (2008). Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma, 8(5), 283-286. [More Information]
  • Burgess, P., Robin, H., Langshaw, M., Kershaw, G., Pathiraja, R., Yuen, S., Coad, C., Xiros, N., Mansy, G., Coleman, R., Gibson, J., Joshua, D., et al (2008). Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert Module. International Journal of Laboratory Hematology, Early View 2008(31 (6)), 1-12. [More Information]

2007

  • Grigg, A., Gibson, J., Bardy, P., Reynolds, J., Shuttleworth, P., Koelmeyer, R., Szer, J., Roberts, A., To, L., Kennedy, G., Bradstock, K. (2007). A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biology of Blood and Marrow Transplantation, 13(5), 560-567. [More Information]
  • Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. Molecular Cancer Therapeutics, 6(12), 3365s-3366s.
  • Sanders, J., Crawford, B., Gibson, J., Ho, J., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
  • Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), Clinical Malignant Haematology, (pp. 847-857). United States: McGraw Hill.
  • Feyler, S., Prince, H., Pearce, R., Towlson, K., Nivison-Smith, I., Schey, S., Gibson, J., Patton, N., Bradstock, K., Marks, D., et al (2007). The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplantation, 40(5), 443-450. [More Information]
  • Joshua, D., Brown, R., Sze, D., Hodges, P., Gibson, J. (2007). The role of T-cells in myeloma. XIth International Myeloma Workshop & IVth International Workshop on Waldenstrom’s Macroglobulinemia, Italy: Fondazione Ferrata Storti.

2006

  • Gibson, J., Anagnostopoulos, A., Hari, P., Pérez, W., Ballen, K., Bashey, A., Bredeson, C., Freytes, C., Gale, R., Gertz, M., et al (2006). Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biology of Blood and Marrow Transplantation, 12(8), 845-854. [More Information]
  • Sze, D., Brown, R., Yang, S., Ho, J., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. Current Cancer Drug Targets, 6(4), 325-331. [More Information]
  • Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, J. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]

2005

  • Gibson, J., Joshua, D., Ho, J., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), Oxford Handbook of Music Psychology. Oxford, UK: Oxford University Press.
  • Gibson, J., Prosser, I., Spencer, A., Horvath, N., Prince, R., Herrmann, R., Bashford, J., Joske, D., Grigg, A., McKendrick, J., et al (2005). Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation, 35(10), 971-7. [More Information]

2004

  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. Leukemia and lymphoma, 45(2), 363-371.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β�? In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748.
  • Gibson, J., Ho, J., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic. Transplantation Proceedings, 36(8), 2501-2503. [More Information]
  • Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., Wolf, M., Gibson, J., Schwarer, A., Spencer, A., et al (2004). Interferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia. Annals of Oncology, 15(12), 1810-1815.
  • Horvath, N., Hahn, U., Joshua, D., Dyson, P., Gibson, J., Stevens, J., Rawling, T., Barrow, L., Brown, R., Stephens, S., et al (2004). Long-Term Follow Up Of Sequential Mobilisation And Autologous Transplantation With Cd34-Selected Cells In Multiple Myeloma: A Multimodality Approach. Internal Medicine Journal, 34, 167-175.
  • Gibson, J., Ho, J., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. Transplantation Proceedings, 36(7), 1995-1998. [More Information]
  • Szer, J., Durrant, S., Schwarer, A., Bradstock, K., Gibson, J., Arthur, C., To, L., Hughes, T., Raunow, H. (2004). Oral Versus Intravenous Ganciclovir For The Prophylaxis Of Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation. Internal Medicine Journal, 34(3), 98-101.
  • Joshua, D., Gibson, J., Brown, R., Ho, J. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), Multiple myeloma and related disorders, (pp. 29-46). UK: Hodder Arnold.
  • Ho, J., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. American Journal of Cancer, 3(1), 47-66.

2003

  • Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, J., Raitakari, M., Basten, A., Joshua, D., Fazekas, B. (2003). Clonal Cytotoxic T Cells in Myeloma. Leukemia and lymphoma, 44(10), 1667-1674.
  • Barrow, L., Brown, R., Murray, A., Sze, D., POPE, B., Gibson, J., Hart, D., Joshua, D. (2003). CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination. Leukemia and lymphoma, 44(12), 2117-2122.
  • Gibson, J., et, A. (2003). Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102(10), 3521-3529.
  • Sze, D., Brown, R., Yang, S., Gibson, J., Ho, J., Fazekas, B., Basten, A., Joshua, D. (2003). Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia and lymphoma, 44(9), 1557-1568.
  • Raitakari, M., Brown, R., Gibson, J., Joshua, D. (2003). T cells in myeloma. Hematological Oncology, 21(1), 33-42. [More Information]

2002

  • Ho, J., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. Reviews in Clinical and Experimental Hematology, 6(3), 276-300.

2001

  • Nivison-Smith, I., Bradstock, K., Szer, J., Durrant, S., Dodds, A., Hermann, R., Schwarer, A., Gibson, J., To, L., Arthur, C. (2001). Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplantation, 28(1), 21-27.
  • Sze, D., Giesajtis,, G., Brown, R., Raitakari, M., Gibson, J., Ho, J., Baxter, A., Fazekas, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment. Blood, 98(9), 2817-2827.
  • Brown, R., POPE, B., Murray, A., Esdale, W., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-B1 and interleukin-10. Blood, 98(10), 2992-2998.
  • Ho, J., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood, 97, 490-495.

To update your profile click here. For support on your academic profile contact .